ArriVent BioPharma Falls Sharply on Mixed Phase 1 Results for CDH17 ADC

ArriVent BioPharma stock dropped sharply on Oct. 26 as investors questioned the confirmed response rate in early ARR-217 Phase 1 data for GI cancers.